Top

Cancer Chemotherapy and Pharmacology

Published in:

01-03-2005 | Original Article

Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study

Authors: M. Schena, C. Barone, N. Birocco, D. Dongiovanni, G. Numico, I. Colantonio, O. Bertetto

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2005

Abstract

Background

Cisplatin, paclitaxel and 5-fluorouracil (5-FU) have demonstrated significant activity in patients with advanced squamous head and neck cancer (HNSCC) despite relevant toxicity. A weekly administration of cisplatin and paclitaxel with continuous infusion of 5-FU could offer a better toxicity profile without affecting dose intensity or treatment outcome. We evaluated the toxicity and the activity of weekly cisplatin/paclitaxel with continuous infusion 5-FU in patients with recurrent and/or metastatic HNSCC.

Methods

A total of 44 patients were studied. Treatment consisted of two 6-week cycles with weekly cisplatin 20 mg/m² and paclitaxel 60 mg/m² and daily continuous infusion 5-FU 200 mg/m² from day 1 to 42. Patients were evaluated for toxicity and response.

Results

40 out of 44 patients were evaluable for response. After two cycles we observed seven complete responses (16%) and 12 partial responses (27%), with a 43% (95% CI 28–58%) overall response rate. Stable disease was seen in 13 patients (29%) and progressive disease in 12 patients (27%). Toxicity was mild in treated patients: we observed less than 10% of grade 3/4 hematological and gastroenteric toxicity.

Conclusions

A weekly schedule of cisplatin and paclitaxel associated with continuous infusion 5-FU showed low toxicity in the treatment of advanced HNSCC while significant activity was conserved.

Boring CG, Squires TS, Tong T (1992) Cancer statistics 1992. CA Cancer J Clin 42:19–38PubMed

Zbaren P, Lehmann W (1987) Frequency and sites of distant metastases in head and neck squamous-cell carcinoma. Arch Otolaryngol Head Neck Surg 113:762–764PubMed

Vokes EE, Weichselbaum RR, Lippman S, et al (1993) Head and neck cancer. N Engl J Med 328:184–194CrossRefPubMed

Morton RP, Rugman F, Dorman EB, et al (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15(3):283–289CrossRefPubMed

Forastiere AA, Metch B, Schuller DE, et al (1992) Randomized comparison of cisplatin plus 5-fluorouracil versus carboplatin plus 5FU versus methotrexate in advanced squamous cell carcinoma of the head and neck. Clin Oncol 10(8):1245–1251PubMed

Pinto HA, Jacobs C (1991) Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 5:667–686PubMed

Forastiere AA (1993) Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 20 [Suppl 3]:56–60

Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Hong WSM (1997) Recent advances in paclitaxel containing chemotherapy for metastatic squamous cell carcinoma of the head and neck. Semin Oncol 24(6 suppl 19):S19-33–S19-37

Forastiere AA, Shank D, Neuberg D, et al (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82(11):2270–2274PubMed

10.

Hitt R, Hornedo J, Colomer R, et al (1997) Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol 24(1 Suppl 2):S2-8–S2-64

11.

Forastiere AA, Leong T, Rowinsky E, et al (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: an Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19(4):1088–1095PubMed

12.

Benasso M, Numico G, Rosso R, et al (1997) Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose finding study. Semin Oncol 24(6 suppl 19):S19-46–S19-50

13.

Hussain M, Gadgeel S, Kucuk O, et al (1999) Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 86(11):2364–2369CrossRefPubMed

14.

Shin DM, Glisson BS, Khuri FR, et al (1998) Role of paclitaxel, ifosfamide and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 25(2 Suppl 4):40–44

15.

Patel K, Anthney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT (2004) Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 15:568–573CrossRefPubMed

16.

Fizazi K, Zelek L (2000) Is ‘one cycle every three or four weeks’ obsolete? A critical review of dose-dense chemotherapy in solid neoplasm. Ann Oncol 11:133–149CrossRefPubMed

17.

Kish JA, Ensley JF, Jacobs J, et al (1985) A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56(12):2740–2744PubMed

18.

Weiner LM, Colarusso P, Goldberg M, et al (1997) Combined-modality therapy for esophageal cancer: a phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 24(6 suppl 19):S19-93–S10-95

19.

Goldberg M, Farma J, Lampert C, et al (2003) Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5 fluorouracil and radiation in resectable esophageal carcinoma: a phase I report. J Thorac Cardiovasc Surg 126(4):1168–1173CrossRefPubMed

20.

Miller AB, Hoogstraten B, Staquet M, et al (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMed

21.

Van Oosterom A (1992) Tumor eligibility and response criteria for phase II and III studies and (sub)acute toxicity grading with suggested amendments to WHO criteria. EORTC Data Center Producers Manual, 2nd edn. EORTC, pp 119–133

22.

Simon R (1989) Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1–10CrossRefPubMed

23.

Degardin M, Oliveira J, Geoffrois L, et al (1998) An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 9:1103–1107CrossRefPubMed

24.

Catimel G, Vermorken JB, Clavel M, et al (1994) A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5(6):543–547

25.

Koussis H, Chiarion-Sileni V, Scola A, et al (2000) Carboplatin plus vinorelbine in head and neck or oesophageal carcinoma in the elderly or in patients with poor performance status (PS): preliminary report. Ann Oncol 11 [Suppl 4]:94

26.

Fountzilas G, Stathopoulos G, Nicolaides C, et al (1999) Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 10(4):475–478CrossRefPubMed

27.

Hitt R, Castellano D, Hidalgo M, et al (1998) Phase II trial of cisplatin and gemcitabine in advanced squamous cell carcinoma of the head and neck. Ann Oncol 9(12):1347–1349CrossRefPubMed

28.

Espinosa E, Zamora P, Milla A, et al (2002) A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 24(12):1054–1059CrossRefPubMed

29.

Haddad RI, Van Echo DA (2003) Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol 52(4):303–306CrossRefPubMed

30.

Murphy B, Li Y, Cella D, et al (2001) Phase III study comparing cisplatin (C) & 5-Fluorouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck cancer (MHNC). Proceedings of ASCO No. 894

Title: Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study
Authors: M. Schena
C. Barone
N. Birocco
D. Dongiovanni
G. Numico
I. Colantonio
O. Bertetto
Publication date: 01-03-2005
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-004-0875-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2005

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system

Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors

DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells

Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-α and translocating PKC-δ

Control of Atm−/− thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer